middle.news

Neuren’s DAYBUE Sales Climb 11% as European Launch Nears

3:00am on Monday 2nd of June, 2025 AEST Pharmaceuticals
Read Story

Neuren’s DAYBUE Sales Climb 11% as European Launch Nears

3:00am on Monday 2nd of June, 2025 AEST
Key Points
  • Q1 2025 DAYBUE US net sales up 11% to US$84.6 million
  • Neuren’s Q1 2025 royalty income rises 17% to A$13.5 million
  • Record 954 unique patients treated, with improved persistency rates
  • Full-year 2025 US sales guidance maintained at US$380–405 million
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about NEU
OPEN ARTICLE